Switzerland-based Carbogen Amcis AG, a pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, said its Hunzenschwil (Neuland), Switzerland API manufacturing site has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection.   The four-day, pre-approval inspection was undertaken by an FDA investigator from July 8-11, 2019. The inspection was concluded with no Form 483’s filed, thus confirming that no critical or major o...